middle easten
Outlook 2021: Tackling the trilemma

Outlook 2021: Tackling the trilemma

19-11-2020 | Yearly outlook

Finding the right balance between three things – public health, normal economic functioning, and personal freedoms – will be the main challenge for policymakers in 2021. As these problems surfaced with the Covid-19 outbreak, it can be expected that a vaccine would solve most of the problems.

  • Jeroen Blokland
    Jeroen
    Blokland
    Portfolio Manager
  • Peter van der Welle
    Peter
    van der Welle
    Strategist Global Macro team, Robeco
  • Ernesto Sanichar
    Ernesto
    Sanichar
    Senior Portfolio Manager

In general, we believe 2021 will be a good year for risky assets, with equities realizing above average returns in our base case. However, in a scenario in which a working Covid-19 vaccine is not readily available to a large part of the global population in 2021, all bets are off and all risky assets will realize negative returns.

This article is one of the special topics in our 2021 Outlook ‘Tackling the trilemma’
This article is one of the special topics in our 2021 Outlook ‘Tackling the trilemma’
Read more

Leave your details and download our full 2021 Outlook

Disclaimer

This report is not available for users from countries where the offering of foreign financial services is not permitted, such as US Persons.

Your details are not shared with third parties. This information is exclusively intended for professional investors. All requests are checked.

Logo

Disclaimer

Robeco Institutional Asset Management B.V. (DIFC Branch) is regulated by the Dubai Financial Services Authority (“DFSA”) and only deals with Professional Clients and Market Counterparties, and does not deal with Retail Clients as defined by the DFSA.

Neither information nor any opinion expressed on the website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. An investment in a Robeco product should only be made after reading the related legal documents such as management regulations, prospectuses, annual and semi-annual reports, which can be all be obtained free of charge at this website and at the Robeco offices in each country where Robeco has a presence.

Please confirm that you are a professional investor and/or institutional investor and that you have read, understood and accept the terms of use for this website.

I Disagree